<DOC>
	<DOCNO>NCT01235507</DOCNO>
	<brief_summary>This open-label , single arm study assess safety efficacy RoActem ra/Actemra ( tocilizumab ) combination methotrexate patient activ e moderate severe rheumatoid arthritis inadequate response dis ease-modifying antirheumatic drug ( DMARDs ) . Patients receive RoActemra/Act emra dose 8 mg/kg ( maximum 800 mg ) intravenously every 4 week tot al 6 infusion . Methotrexate continue stable dose . Anticipated time study treatment 24 week .</brief_summary>
	<brief_title>A Study RoActemra/Actemra ( Tocilizumab ) Combination With Methotrexate Patients With Active Rheumatoid Arthritis Who Have Inadequate Response Disease-Modifying Antirheumatic Drugs ( DMARDs ) ( ALABASTER )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Active moderate severe rheumatoid arthritis ( RA ) On methotrexate treatment ( oral parenteral ) least 12 week , stable dose least 15 mg/week least 6 week Oral corticosteroid must stable dose &lt; /= 10 mg/day prednisone ( equivalent ) least 25 28 day prior first dose study drug Body weight &lt; /= 150 kg Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month study entry Rheumatic autoimmune disease RA Functional class IV accord American College Rheumatology ( ACR ) classification Prior history current inflammatory joint disease RA Treatment traditional DMARDs methotrexate within 1 month ( leflunomide 3 month ) prior baseline Treatment biologic drug use treatment RA Intraarticular parenteral corticosteroid within 6 week prior baseline Known active current history recurrent infection History currently active primary secondary immunodeficiency Positive HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>